mycophenolate mofetil (Cellcept)

01/01/2012 - "Clinical trials revealed a high efficacy of mycophenolate mofetil (MMF)in inducing and maintaining remission in patients with class III-V-lupus nephritis. "
11/01/2005 - "Short-term to intermediate-term, randomized controlled trials have shown that mycophenolate mofetil is a good option for the induction and maintenance of remission in lupus nephritis patients. "
11/24/2005 - "Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable. "
07/01/2011 - "To determine the timing for safe reduction of mycophenolate mofetil (MMF) dose during remission-maintenance therapy of proliferative lupus nephritis. "
01/01/2008 - "The efficacy of mycophenolate mofetil in the treatment of patients with lupus nephritis has been recently established in several clinical trials. "

08/01/2011 - "Mycophenolate mofetil was efficient in inducing and maintaining remission of nephrotic syndrome. "
02/01/2008 - "The results suggest that mycophenolate mofetil is effective and safe in preventing relapses in steroid-dependant nephrotic syndrome. "
09/01/2005 - "Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome."
03/01/2000 - "Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil."
03/01/2012 - "Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial."

01/01/2015 - "Mycophenolate mofetil (MMF) has recently been reported to be effective in the treatment of systemic lupus erythematosus (SLE). "
04/01/2012 - "Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). "
10/01/2011 - "Mycophenolate mofetil (MMF) is an immunomodulatory drug shown to be effective in the treatment of systemic lupus erythematosus. "
04/01/2009 - "Mycophenolate mofetil (MMF) is effective in the treatment of patients with active systemic lupus erythematosus (SLE). "
04/01/2009 - "Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study."

06/01/2004 - "The proteinuria improved dramatically following treatment with mycophenolate mofetil. "
01/01/2008 - "Mycophenolate mofetil as a primary therapy in MLN was successful in inducing complete remission in about 40% of MLN, particularly in patients with mild proteinuria. "
01/01/2009 - "The patient was treated with mycophenolate mofetil (1.5 g/day) with a significant improvement in proteinuria."
05/01/2012 - "Our aim was to evaluate the efficacy of mycophenolate mofetil (MMF) for treating pediatric patients with HSPN and nephrotic-range proteinuria. "
01/01/2013 - "Mycophenolate mofetil can protect renal function by increasing Bcl-2 expression and decreasing Bax expression and podocyte apoptosis rate, thereby reducing proteinuria."

09/01/2015 - "Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?"
01/01/2006 - "We enrolled 11 patients with refractory graft-versus-host disease (GVHD) in a prospective trial evaluating the efficacy of mycophenolate mofetil (MMF). "
05/21/2009 - "We conducted a double-blind, randomized multicenter trial to determine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic treatment of chronic graft-versus-host disease (GVHD). "
04/01/2005 - "Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease."
11/01/2014 - "Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis."